The thesis

Enova International lends to consumers and small businesses through installment loans, credit lines, and CSO programs in the United States and Brazil. The numbers are strong: revenue grew 25.7% year over year, gross margin is 60.6%, net margin is 10.5%, and the stock trades at 11.4x earnings. Analysts rate it a buy, but our conviction score is 4 out of 100, dormant, and the risk-on rotation that would normally lift fintech names is inactive. The tension is the point: fundamentals and consensus say buy, while the momentum signal says the macro driver has not yet engaged.

Why now

A 25.7% growth rate at an 11.4x multiple prices Enova as if the story stalls, leaving valuation little room for optimism and much room for surprise. The inactive risk-on rotation is the unresolved catalyst: when sentiment turns, the gap between dormant positioning and strong fundamentals becomes the trade.

What to watch

Watch quarterly revenue growth against the 25.7% benchmark and any drift in net margin below 10.5% as the first sign of credit stress. Watch for activation of the risk-on rotation into fintech and any regulatory action on consumer lending; those two signals resolve whether the dormant conviction score was early or right.

Key risks

Enva's book is consumer and small-business credit, so a downturn in credit quality hits revenue and the 10.5% net margin directly. Regulators in the United States and Brazil can cap rates or curtail CSO programs, invalidating the growth model. If the 25.7% growth decelerates while the rotation stays inactive, the cheap multiple gets cheaper and the consensus buy thesis erodes.

Theme exposure